Safety and efficacy of azacitidine in myelodysplastic syndromes

Carlos E. Vigil, Taida Martin-Santos, Guillermo Garcia-Manero

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m2 daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label Recommendations were also analyzed. Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.

Original languageEnglish (US)
Pages (from-to)221-229
Number of pages9
JournalDrug Design, Development and Therapy
StatePublished - 2010
Externally publishedYes


  • Azacitidine
  • Hypomethylating agents
  • MDS

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Safety and efficacy of azacitidine in myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this